Thornburg Investment Management Inc. Trims Stake in Novo Nordisk A/S (NYSE:NVO)

Thornburg Investment Management Inc. decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 5.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 721,148 shares of the company's stock after selling 38,043 shares during the period. Novo Nordisk A/S makes up about 0.8% of Thornburg Investment Management Inc.'s holdings, making the stock its 29th largest holding. Thornburg Investment Management Inc.'s holdings in Novo Nordisk A/S were worth $62,033,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Toronto Dominion Bank raised its stake in Novo Nordisk A/S by 494.1% in the fourth quarter. Toronto Dominion Bank now owns 88,295 shares of the company's stock valued at $7,595,000 after purchasing an additional 73,432 shares in the last quarter. Silvercrest Asset Management Group LLC grew its position in Novo Nordisk A/S by 3.1% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 127,998 shares of the company's stock worth $11,010,000 after acquiring an additional 3,881 shares in the last quarter. Sphera Funds Management LTD. increased its stake in Novo Nordisk A/S by 25.6% in the fourth quarter. Sphera Funds Management LTD. now owns 98,080 shares of the company's stock valued at $8,437,000 after acquiring an additional 20,000 shares during the last quarter. Polar Asset Management Partners Inc. lifted its stake in Novo Nordisk A/S by 86.0% during the fourth quarter. Polar Asset Management Partners Inc. now owns 27,900 shares of the company's stock worth $2,400,000 after purchasing an additional 12,900 shares during the last quarter. Finally, Quadcap Wealth Management LLC boosted its holdings in shares of Novo Nordisk A/S by 84.4% in the 4th quarter. Quadcap Wealth Management LLC now owns 3,623 shares of the company's stock worth $312,000 after purchasing an additional 1,658 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating on the stock. Finally, Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $64.35 on Friday. The company has a 50-day simple moving average of $67.31 and a two-hundred day simple moving average of $84.38. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a market capitalization of $288.75 billion, a PE ratio of 19.56, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.